• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Summary of status of development and availability of avian influenza A(H7N9) candidate vaccine viruses (WHO, September 26 2013)

Giuseppe

Emeritus
[Source: World Health Organization, full PDF document: (LINK). Edited.]


Summary of status of development and availability of avian influenza A(H7N9) candidate vaccine viruses

26 September 2013


Parent virus - Candidate vaccine virus - Type of virus or reassortant - Developing institute - Available from
  • A/Shanghai/2/2013 Synthetic HA&NA
    • IDCDC-RG32A* - Reverse genetics - CDC, USA - CDC, USA
    • NIBRG-267* - Reverse genetics - NIBSC, UK - NIBSC, UK
    • CBER-RG4A* - Reverse genetics - CBER, USA - CBER, USA
  • A/Anhui/1/2013
    • Wild type virus - WHO CCs
    • NIBRG-268* - Reverse genetics - NIBSC, UK - NIBSC, UK
    • NIIDRG-10.1* - Reverse genetics - NIID, Japan - NIID, Japan
    • IDCDC-RG33A** - Reverse genetics - CDC, USA - CDC, USA
* These viruses are candidate vaccine viruses which have passed relevant safety testing and two-way haemagglutination inhibition (HI) tests. They can be handled under BSL-2 enhanced containment(1).

** This is a potential candidate vaccine virus which has passed two-way haemagglutination inhibition (HI) tests but the safety testing is still being finalized. It must be handled under BSL-3 containment.
____

Institutes contact details for candidate vaccine viruses orders/information:
Sheep antisera

[Antisera directed against: - Order Lot # - Available from]
  • *A/Anhui/1/2013-like
    • 13/180 - 13/166# - NIBSC, UK
# Anti NA serum for tests of Neuraminidase identification

*new reference antisera
_____

The above-listed potency testing reagents for A(H7N9) vaccines have been developed with support from WHO CCs and Essential Regulatory Laboratories (ERLs) and calibrated by the ERLs that provide advice to WHO as part of the influenza vaccine virus selection and development process.

ERLs contact details for reagent orders and other information:
For general enquiries, please contact gisrs-whohq@who.int

For other candidate vaccine viruses and potency testing reagents, please go to http://www.who.int/influenza/vaccines/virus/candidates_reagents/home/


-
-------
 
Back
Top Bottom